TCI GENE Inc. (TPEX:6879)

Taiwan · Delayed Price · Currency is TWD

36.50

-0.50 (-1.35%)

Jul 14, 2026, 12:23 PM CST

-12.68% (1Y)

Market Cap	965.74M -12.6%
Revenue (ttm)	273.61M -21.3%
Net Income	40.57M -28.0%
EPS	1.52 -28.3%
Shares Out	26.46M
PE Ratio	24.01
Forward PE	n/a
Dividend	2.00 (5.41%)
Ex-Dividend Date	Sep 5, 2025

Volume	17,060
Open	35.15
Previous Close	37.00
Day's Range	35.15 - 37.00
52-Week Range	32.45 - 47.35
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 4, 2026

About TCI GENE

TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-der... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 6879

Full Company Profile

Financial Performance

In 2025, TCI GENE's revenue was 273.61 million, a decrease of -21.27% compared to the previous year's 347.54 million. Earnings were 40.57 million, a decrease of -27.96%.

Financial Statements